INTERNATIONAL JOURNAL OF INFORMATION TECHNOLOGY - Volume 40 issue 1, 2021
Pages: 476-489
Advanced glycation end products and their receptors level among type II diabetes mellitus in Iraq: A Case-Control Study
Hawraa S. Aljubawi1*, Sami R. Alkatib2 Hayder K. Hassoun3
Category: subject-2
Download PDF
Abstract:
Objective: To detect if there is any association between serum level of AGE and RAGEwith occurrence and severity of diabetic peripheral neuropathy. Patients and method: The study include 149 patients with type 2 diabetes, those patients recruited from diabetic center in Marjan medical city from Babylon governorateand diabetic center in Al-Sadr medical city from Alnajaf Alashrafgovernorate in the middle of Iraqduring the period from June 2019 to April 2020 .The patients is divided in to 2 group( group I with neuropathy and group II without neuropathy ) according to the presence or absence of peripheral neuropathy depending on clinical assessment and results of neurophysiologic studies including conductive velocity, distal latency, amplitude for both sensory and motor nerves of upper and lower limbs. The results were analyzed in relation to AGE and RAGE blood level and compared with matched control group. Both patients and controls sent for biochemical assessment including random blood sugar, glycated hemoglobin. Results: The study found that the serum level of AGEwas significantly higher in patients with diabetic neuropathy than in patients without neuropathy (4146.86±2171.87 VS1299.78±1098.33pg/ml) P <0.001.The study also found that the level of RAGE was also significantly higher in patients with DPN than in patients without DPN (2945.12±1378.08 VS 1185.47±724.79 pg/ml) P <0.001.The serum level of AGE and RAGE constantly and significantly increased with the severity of diabetic peripheral neuropathy. Conclusions: There is significant association between AGE & RAGE serum level with occurrence and severity of diabetic peripheral neuropathy.
Keywords: Receptors, advanced glycation, end products, diabetic peripheral neuropathy
References:
1. Davidsons. (2018). Daibetis mellitus: Principles and Practice of Medicine,23th edit. Diabetic Peripheral Neuropathy: A Comprehensive differences in risk, pathophysiology and complications of type 2 diabetes mellitus, Endocrine Reviews, vol. 37, no. 3, pp. 278–316
.2. International Diabetes Federation, IDF Diabetes Atlas, International Diabetes Federation, pp. 80- 81, 8 edition, 2017.
3. S. Singh.(2012). The genetics of type 2 diabetes mellitus: a review, Journal of Scientific Research, vol. 55, pp. 35–48.
4. Bucciarelli, L. G., Wendt, T., Qu, W., Lu, Y., Lalla, E. and Rong.(2012). RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 106, 2827–2835
5. Yamamoto, Y., Yamagishi, S., Yonekura, H., Doi, T and Tsuji, H.(2014). Roles of the AGE-RAGE system in vascular injury in diabetes. Ann. N. Y. Acad. Sci. 902, 163–170
6. Yonekura, H., Yamamoto, Y., Sakurai, S., Petrova and R. G. Abedin.(2013). Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097–1109.
7. Geroldi, D., Falcone, C. and Emanuele, E.(2016). Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13, 1971–1978.
8. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W and Lu Y.(2013).RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 162:1123-1137. doi: 10.1016/S0002-9440(10)63909-0.
9. Perkins BA, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods. Clinical Neurophysiology 2003;114(7):1167?75
10. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001)J. Clin. Invest. 108, 949–955.
11. Huttunen, H. J., Kuja-Panula, J., Sorci, G., Agneletti, A. L., Donato, R., and Rauvala, H. (2000) J. Biol. Chem. 275, 40096–40105
12. Sajithlal, G., Huttunen, H., Rauvala, H., and Munch, G. (2002) J. Biol. Chem. 277, 6888– 6897.
13. Uribarri J., Cai W., Peppa M., Goodman S., Ferrucci L., Striker G., Vlassara H.(2007). Circulating glycotoxins and dietary advanced glycationendproducts: two links to inflammatory response, oxidative stress, and aging. J. Gerontol. A Biol. Sci. Med. Sci. 62:427–433.
14. Vlassara H., Cai W., Goodman S., Pyzik R., Yong A., Chen X., Striker G.E and Uribarri J.(2009). Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: Role of the anti-inflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 94:4483–4491.
15. Yamagishi S, Adachi H, Nakamura K and Matsui T.(2006). Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 55 (9): 1227-1231. 37.
16. Nakamura K, Yamagishi S, Adachi H and Matsui T.(2008).Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulatingAGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 2008; 76 (1): 52-56.
17. He CT, Lee CH, Hsieh CH, Hsiao FC, Kuo P and Chu NF.(2014).Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. Int J Endocrinol. 2014;2014:657607.
18. Rowisha M, El-Batch M, El Shikh T, El Melegy S and Aly H. (2016). Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks. Pediatr Res. Jul;80(1):67–71.
19. Gohda T, Tanimoto M, Moon JY, Gotoh H, Aoki T and Matsumoto M .(2008). Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res ClinPract 81:196–201
20. Brownlee M (2011)Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223–234.
21. Vlassara H (2012). Advanced glycation end-products and atherosclerosis. Ann Med 28:419– 426.
22. Haitoglou CS, Tsilibary EC, Brownlee M and Charonis AS (2012). Altered cellular interactions between endothelial cells and nonenzymaticallyglucosylatedlaminin/type IV collagen. J BiolChem 267:12404–12407.
23. Selvin E, Halushka MK and Rawlings AM (2013).sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62:2116–2121.
24. Thomas MC, Söderlund J and Lehto M.(2011). Study Group Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 54:2669–2677.
25. Aubert CE, Michel PL, Gillery P, Jaisson S, Fonfrede M and Morel F.(2014). Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes. Diabetes Metab Res Rev 30:679–685.
|